ERBB2 and neoplasm: Our results suggest that this chemo-free regimen has anti-tumor activity in HER2-positive ABC, including HR-negative, HER2-positive patients, and exhibits efficacy in patients with BM, providing an alternative fully oral regimen for patients with HER2-positive ABC.